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SUMMARY 
PTPRB is a transmembrane protein tyrosine phosphatase known to regulate blood vessel 
remodelling and angiogenesis. Here we demonstrate that PTPRB negatively regulates 
branching morphogenesis in the mammary epithelium. We show that Ptprb is highly 
expressed in adult mammary stem cells and also, although at lower levels, in estrogen 
receptor positive luminal cells. During mammary development Ptprb expression is down-
regulated during puberty, a period of extensive of ductal outgrowth and branching. In vivo 
shRNA knockdown of Ptprb in the cleared mammary fat pad transplant assay resulted in 
smaller epithelial outgrowths with an increased branching density and also increased 
branching in an in vitro organoid assay. Organoid branching was dependent on stimulation by 
FGF2, and Ptprb knockdown in mammary epithelial cells resulted in a higher level of FGFR 
activation and ERK1/2 phosphorylation, both at baseline and following FGF2 stimulation. 
Therefore, PTPRB regulates branching morphogenesis in the mammary epithelium by 
modulating the response of the FGFR signalling pathway to FGF stimulation. Considering 
the importance of branching morphogenesis in multiple taxa, our findings have general 
importance outside mammary developmental biology.  
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INTRODUCTION 
The mammary gland is a highly dynamic organ; limited embryonic development is followed 
by extensive postnatal pubertal development with further differentiation and tissue 
remodelling occurring during pregnancy and lactation (Macias and Hinck, 2012). A key 
aspect of mammary epithelial structure formation is branching morphogenesis, a patterning 
event driven by systemic and local cues (Sternlicht, 2006). During pubertal development, 
branching morphogenesis is dependent on the balance between the rate of ductal extension 
driven by Terminal End Buds (TEBs; specialised growth structures at the tips of the 
developing ducts), the rate of TEB bifurcation and, in the later stages of development, the 
formation of lateral branches from established ducts. As branching morphogenesis is a 
common developmental process in many tissues in many taxa, understanding its regulation in 
the mammary gland can have implications beyond a single system and can inform paradigms 
of development across the animal kingdom. 
 
The growth of TEBs, and thus of the subtending ducts, is driven by one or more stem cell 
population(s) which generate the two main mammary epithelial lineages (‘basal’ and 
‘luminal’) during puberty (Williams and Daniel, 1983; Ball, 1998; Srinivasan et al., 2003). 
Stem cells dispersed throughout the mature mammary epithelium are also thought to be 
important for maintenance of the adult non-pregnant gland, although the nature of these 
remains controversial (Van Keymeulen et al., 2011; Rios et al., 2014; Wang et al., 2015). It is 
clear, however, that the basal layer contains a small population of cells with potent outgrowth 
potential in mammary fat pad transplant experiments and which upon transplantation 
regenerate complete basal and luminal layers, consistent with a stem cell identity (Shackleton 
et al., 2006; Sleeman et al., 2006; Stingl et al., 2006). In addition to this transplantable stem 
cell population, the basal layer consists mainly of contractile myoepithelial cells. The luminal 
layer consists of populations of progenitors (Regan et al., 2012) as well as functionally 
differentiated cells, including hormone-sensing ER positive (ER+) cells and the secretory ER 
negative (ER-) cells found in the alveoli during lactation. The luminal progenitors are mainly 
ER- (Regan et al., 2012). The molecular regulation of epithelial homeostasis in these stem-
progenitor-differentiated populations, and how this homeostasis contributes to tissue 
morphogenesis, remains an area of intense interest. 
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PTPRB, also known as RPTP and VE-PTP, is a highly promiscuous R3 type receptor 
protein tyrosine phosphatase which can dephosphorylate multiple receptor tyrosine kinases 
(Barr et al., 2009). It consists of a single intracellular catalytic domain with C-terminal 
phosphorylation sites, a transmembrane domain and an extracellular domain with multiple 
fibronection type III-like domains (Matozaki et al., 2010). Binding by heparin binding 
domain-containing growth factors, such as pleiotropin, cause dimerization and inactivation 
(Maeda and Noda, 1998). The role and functions of PTPRB have been most fully described 
in the development of the embryonic vasculature (Baumer et al., 2006; Dominguez et al., 
2007) and in arterial endothelial cells, in which the two main targets of PTPRB have been 
identified as the receptor tyrosine phosphatase TEK and vascular endothelial cadherin / 
cadherin 5 (VE-cadherin / CDH5). PTPRB activity enhances VE-cadherin-mediated adhesion 
(Nawroth et al., 2002) but is a negative regulator of TEK (Baumer et al., 2006; Dominguez et 
al., 2007). 
 
We recently identified a set of 323 genes, including Ptprb, whose expression was specifically 
associated with the transplantable basal mammary stem cell (MaSC) population in the adult 
mouse mammary epithelium (Soady et al., 2015). As a regulator of morphogenesis in other 
systems, we hypothesised that PTPRB may also be a regulator of mammary development. 
However, owing to the embryonic lethality of Ptprb gene ablation and the lack of a 
conditional knockout model, the functional role of PTPRB in postnatal mammary gland 
development has not previously been studied. We have therefore exploited the potential of 
cleared fat pad transplantation in an in vivo functional genomics approach as well as in vitro 
mechanistic studies to determine whether PTPRB is required for normal mammary 
morphogenesis. We find that PTPRB is a negative regulator of branching morphogenesis, 
acting by modulating signalling downstream of FGFR. These results have general importance 
for understanding the regulation of epithelial branching morphogenesis. 
 
  
Soady et al.  PTPRB and mammary morphogenesis 
5 
 
RESULTS 
Expression patterns of Ptprb in the mammary epithelium alter during postnatal 
mammary development 
In an Affymetrix microarray-based analysis of gene expression in the adult (10-12 week old) 
mammary epithelium comparing highly purified MaSCs with the other major epithelial 
subpopulations (myoepithelial cells, luminal ER- progenitors and luminal ER+ differentiated 
cells) we identified a 323 MaSC gene signature that included Ptprb (Soady et al., 2015). We 
hypothesised that PTPRB may be a regulator of mammary morphogenesis. 
 
To test this hypothesis, we evaluated Ptprb expression by quantitative real-time reverse 
transcriptase PCR (qPCR) during post-natal mammary gland development in highly purified 
primary mammary epithelium subpopulations isolated by flow cytometry at three 
developmental time-points. MaSCs, myoepithelial (MYOs), luminal ER- progenitors 
(LumER-) and luminal ER+ differentiated (LumER+) cells were isolated from female FVBn 
mice as previously described (Regan et al., 2012; Soady et al., 2015) (supplementary material 
Fig.S1). The developmental stages assessed covered pubertal mammary gland morphogenesis 
with three time points representing the onset/early stages of pubertal development (3-4 
weeks), mid-puberty (5-6 weeks) and late puberty/young adulthood (8-10 weeks) (Fig.1A). 
 
Comparison of expression levels between the populations at each timepoint (Fig.1B) 
demonstrated that at onset of puberty Ptprb was more highly expressed in LumER+ cells than 
in MaSCs (P≤0.01). At mid-puberty, when the majority of ductal outgrowth occurs, Ptprb 
expression was not significantly different between the MaSCs and LumER+ populations. 
Confirming our previous findings from the adult gland (Soady et al., 2015), at 8-10 weeks 
Ptprb was most highly expressed (P≤0.01) in MaSCs. However, at all timepoints, both 
MaSCs and LumER+ cells had significantly higher levels of Ptprb expression than the 
LumER- and MYO populations. 
 
Comparing expression levels between the time points within each cell subpopulation (Fig.1C) 
showed that for each population Ptprb expression was reduced at 5-6 weeks (the period of 
most extensive epithelial expansion and morphogenesis) compared with expression levels at 
3-4 weeks (P≤0.05 for LumER- cells, P≤0.01 for MYOs, MaSCs and LumER+ cells). By 8-
10 weeks, Ptprb expression in MaSCs had returned to 3-4 week levels; however, for the 
LumER+ and MYOs, although Ptprb expression levels were increased compared with 5-6 
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week levels, they remained significantly lower than at 3-4 weeks old (P≤0.01 for both 
populations). 
 
Consistent with the qPCR expression analysis, and the known role of PTPRB in endothelial 
cells, RNAScope in situ hybidisation localised Ptprb to the endothelial cells of blood vessels 
in the 3-week old mammary gland and to a subset of luminal epithelial cells in mammary 
ducts (supplementary material Fig.S2). In the 6-week old gland, Ptprb expression could not 
be detected in the mammary epithelium, either because the numbers of cells expressing was 
very low, or, the expression level per cell had fallen below the threshold for detection by the 
technique. However, at this time Ptprb was expressed in a group of stromal cells surrounding 
the ducts. Finally, at 12 weeks Ptprb was again detected in a subset of luminal cells although 
at much weaker levels (supplementary material Fig.S2), consistent with the qPCR. We did 
not observe basal cells with a Ptprb signal at any age, however, basal mammary stem cells 
are very rare and indeed have never been definitively identified in histological sections, so 
this is not surprising. 
 
As Pptrb expression was below the limits of detection by in situ hybridisation at 6 weeks, to 
determine whether Ptprb was differentially expressed in the two main morphological 
structures of the developing gland, the TEBs and their subtending ducts, a gene expression 
profile data set of microdissected TEBs compared with ducts collected at 6 – 7 weeks was 
mined for Ptprb expression (supplementary material Table S1). This analysis demonstrated 
that Prprb is expressed at significantly lower levels in the TEBs compared to the ducts (1.5-
fold lower; P<0.05). 
 
In summary, Ptprb is most highly expressed in MaSCs and LumER+ cells in the adult 
mammary epithelium, but its expression pattern is dynamically regulated during pubertal 
development. LumER+ cells have a decrease in Ptprb expression at mid-puberty followed by 
a partial recovery; MaSCs also have a decrease in mid-puberty but a strong recovery in the 
adult tissue back to levels seen at pubertal onset. During puberty, Ptprb is expressed at lower 
levels in TEBs than in ducts. The strong recovery of expression in MaSCs compared with the 
partial recovery in LumER+ cells results in the MaSCs becoming the highest expressers of 
Ptprb in the adult gland. 
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Ptprb knockdown promotes branching morphogenesis in vivo 
The correlation between lower levels of Ptprb expression and the period of most intense 
morphogenetic activity in the mammary gland, suggested that PTPRB may be a negative 
regulator of mammary morphogenesis. We tested this in in vivo functional assays. In the first 
series of experiments, primary mouse mammary epithelial cells were transduced in short term 
culture (48 hour) with either a pooled lentiviral supernatant containing two shRNA sequences 
against Ptprb (shPtprb pool consisting of shPtprb 0145 plus shPtprb 3820) or a control 
shRNA designed to target luciferase (shLuc). In a second series of three independent 
experiments, primary cells were transduced in short term culture with one of two different 
lentiviral constructs carrying shRNA sequences targeting Ptprb (shPtprb 0145 or shPtprb 
3820) or with a lentvirus carrying a scrambled sequence (shScr). In both sets of experiments 
the viral vectors also contained GFP to mark transduced cells and supernatants were diluted 
to ensure both control and shPtprb supernatants contained equal viral titres. The efficacy of 
the shPtprb pool and the individual lentiviruses in suppressing Ptprb expression was 
confirmed by qPCR (Fig.2A,B). Transduced cells were transplanted into cleared mammary 
fat pads at 50,000 cells per fat pad. At eight weeks, fat pads were harvested and examined 
under epifluorescent illumination, after which they were processed for flow cytometric 
analysis to assess relative proportions of the epithelial cell populations.  
 
There were no differences in the number of successful outgrowths between the shLuc (8 
outgrowths from 11 transplanted fat pads; n = two independent experiments) and the shPtprb 
pool (11/11; n = two independent experiments) transplants or between the shScr (23/24; n = 
three independent experiments), the shPtprb 0145 (13/13; n = three independent experiments) 
and the shPtprb 3820 (11/13; n = three independent experiments) transplants. However, 
Ptprb-knockdown transplants appeared to be more densely branched but filled less of the 
total area of the fat pad than the control outgrowths (Fig.2C). Quantitation of the area of the 
outgrowths and of the number of branch points per mm2 confirmed that knockdown 
outgrowths were significantly smaller than control outgrowths but more densely branched 
(Fig.2D,E). 
 
Both control and Ptprb-knockdown outgrowths had distinct luminal (keratin 18, K18, 
positive) and basal/myoepithelial (smooth muscle actin, SMA, positive) layers (Fig.3A). 
Flow cytometric analysis of the outgrowths confirmed that there were no differences in the 
proportions of the major epithelial populations (supplementary material Fig.S3). Ki67 
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staining of control and Ptprb-knockdown transplants demonstrated that, at the time point at 
which the transplants were harvested, there was little or no proliferation in control tissue but 
Ptprb-knockdown tissue was highly proliferative (Fig.3B). However, the smaller size and 
denser branching of the knockdown tissue (meaning that sections were more likely to be 
enriched for the TEBs) is an important caveat in this analysis. In the proliferating Ptprb-
knockdown tissue, equivalent numbers of Ki67 positive cells were observed in SMA positive 
basal and SMA negative luminal layers (Fig.3B,C). Little or no cleaved caspase-3, a marker 
of apoptosis, could be detected in either control or Ptprb-knockdown outgrowths 
(supplementary material Fig.S4B). 
 
To determine whether Ptprb knockdown perturbed stem cell function as assessed by 
engraftment potential, GFP-positive regions from a series of successful shScr and shPtprb 
0145 primary transplants were dissected out, digested to single cells and then retransplanted. 
Take rates for secondary transplantation into contralateral fat pads of shScr and shPtprb 0145 
transduced cells were 8/9 for both the control and knockdown cells. Consistent with the 
primary transplants, shPtprb 0145-transduced outgrowths had a significantly smaller area 
than control outgrowths (Fig.3D and supplementary material Fig.S4C). Overall, these 
findings show PTPRB does not affect stem cell engraftment potential or lineage 
determination, but does regulate mammary branching morphogenesis. 
 
Ptprb knockdown promotes branching morphogenesis in an in vitro model system in an 
FGF-dependent manner 
To provide further support for a role for PTPRB in regulating branching morphogenesis and 
to establish a model in which mechanism of action of PTPRB could be addressed, we utilised 
an in vitro branching morphogenesis assay (Ewald et al., 2008). Small fragments of 
mammary epithelial ducts which retain the basal-luminal bilayered architecture (‘organoids’) 
were either left untransduced or transduced with Scr, shPtprb 0145 or shPtprb 3820 
lentiviruses, embedded in Matrigel and treated for five days with medium containing FGF2, 
which stimulates branching in this system (Ewald et al., 2008). The total number of organoids 
and number of branched organoids were counted; branched organoids were defined as an 
organoid with at least one branch protruding from the main spherical body.  
 
Organoid cultures branched only in the presence of FGF2; in the absence of FGF2, Ptprb 
knockdown alone was not sufficient to stimulate branching (supplementary material 
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Fig.S5A). However, knockdown of Ptprb in FGF2-stimulated cultures significantly increased 
(P≤0.05) the number of branched organoids, with 40% of organoids branching in non-
infected and Scr controls to >60% in shPtprb1 0145 and shPtprb2 3820 cultures (Fig.4A). 
The amount of branching in non-infected and Scr controls was consistent with previous 
reports on branching in unmanipulated primary mammary epithelial organoids (Macias et al., 
2011). Therefore, Ptprb knockdown in vitro increased the number of organoids competent to 
branch under FGF2 stimulation.  
 
To assess whether Ptprb knockdown also affected the extent of branching, the degree of 
branching in all branched organoids was ascertained. Branched organoids were catergorised 
into low (1-5 branches), intermediate (6-15 branches) or highly branched (>15 branches) 
organoids (Fig.4B,C). Compared with control cultures, shPtprb 0145 and shPtprb 3820-
transduced organoids had an increase in the proportion of highly branched organoids and a 
reduction in numbers of organoids with low branching levels (Fig.4C). Therefore, in vitro 
knockdown of Ptprb increased both the percentage of branched mammary epithelial 
organoids and the number of branches on each branched organoid, but only under conditions 
of growth factor stimulation. 
 
Endogenous Ptprb expression is downregulated during in vitro branching 
morphogenesis 
In vivo, levels of endogenous Ptprb expression were suppressed during the period of post-
natal mammary development. To determine if similar changes in Ptprb expression occur 
during organoid branching in vitro, and to characterise in more detail the relationship 
between the kinetics of endogenous Ptprb expression and branching, unmanipulated non-
infected organoids were embedded in Matrigel and stimulated with or cultured without FGF2 
for 6 days. Non-stimulated organoids did not grow or branch over the experimental time 
course whereas stimulated organoids expanded in size and produced branches, with the first 
obvious branching apparent by day 4 (Fig.5A). qPCR analysis of Ptprb expression in FGF2-
stimulated branching organoids showed that Ptprb expression was reduced over time in 
stimulated organoids relative to day 0. The reduction in Ptprb expression was significant 
from day 1, decreased further at day 3 and remained low until the end of the time course 
(Fig.5B). 
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To control for the possibility that the decrease in Ptprb expression was related to the time in 
culture rather than correlated with FGF2 stimulation and concomitant branching, levels of 
Ptprb expression in stimulated organoids were compared to non-stimulated organoids at each 
time point (Fig.5C). This demonstrated that Ptprb expression in stimulated organoids was 
significantly lower than in non-stimulated organoids by day 3 and continued to drop at days 4 
and 5. Importantly, these findings showed that the first significant difference between Ptprb 
levels in non-stimulated and stimulated organoids was seen just before (day 3) the stimulated 
organoids initiated branching (day 4). This suggests a temporal correlation between FGF2 
stimulation, Ptprb expression and branching. 
 
PTPRB acts on FGFR – ERK1/2 signalling to inhibit mammary branching 
morphogenesis 
The in vivo and in vitro findings, taken together, suggested that while PTPRB does not 
directly inhibit mammary morphogenesis, it acts as a negative regulator of signalling 
pathways that promote branching morphogenesis. In this model, suppression of Ptprb 
expression would result in either a higher or more sustained level of signalling by pro-
branching pathways. The organoid culture system had already demonstrated that PTPRB 
expression interacted with FGF signalling in vitro. To determine whether there was evidence 
for an interaction between PTPRB and FGF signalling in vivo, and to assess the possibility 
that PTPRB may regulate other signalling pathways associated with mammary branching 
morphogenesis, we used qPCR to examine the expression of three receptor tyrosine kinases 
(Erbb2, Egfr and Tek) previously suggested to interact with PTPRB and with potential roles 
in mammary branching morphogenesis (Wiesen et al., 1999; Chodosh et al., 2000; Andrechek 
et al., 2005). We also examined expression of three receptor kinases, including two members 
of the FGF receptor family (Fgfr1, Fgfr2 and Igfr1), not previously described as interacting 
with PTPRB but known to play an important role in mammary development (Sternlicht et al., 
2006; Lu et al., 2008; Pond et al., 2013). Patterns of expression in the different mammary 
epithelial subpopulations at the 5-6 week developmental time point (when branching 
morphogenesis in the mammary epithelium is maximal) were determined and compared with 
the previously established pattern of Ptprb expression (Fig.6A). This analysis showed a 
strong correlation between Ptprb expression and the patterns of Fgfr2 and Tek expression 
across the subpopulations, but no correlation with Egfr, Fgfr1 or Igfr1 expression. 
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Next, expression of Fgfr2 and Tek across, the 3-4 week, 5-6 week and 8-10 week time course 
was examined and compared with Ptprb (Fig. 6B,C). We concentrated on expression patterns 
in the MaSCs and LumER+ cells, as these two populations showed the highest levels of 
Ptprb, Fgfr2 and Tek at 5–6 weeks. Expression of Tek in LumER+ cells was significantly 
lowered in 5-6 week animals relative to 3- 4 weeks. However, by 8-10 weeks it was back to 
3-4 week levels (Fig.6B). By contrast, Tek levels in MaSCs were not significantly different 
between 3-4 weeks and 5-6 weeks and then fell significantly at 8-10 weeks. Thus, there were 
similarities between Tek and Ptprb expression patterns in LumER+ cells, although these were 
not exact. However, there were no obvious correlations between Tek and Ptprb expression in 
MaSCs (Fig.6C). 
 
Fgfr2 expression levels were not significantly different in the LumER+ cells between 3 – 4 
weeks and 5 – 6 weeks but were significantly increased at 8 – 10 weeks. However, in MaSCs, 
there was a significant increase in Fgfr2 expression at 5 – 6 weeks over 3 – 4 weeks, and then 
a decrease in expression. Therefore, there was no obvious correlation between Ptprb and 
Fgfr2 expression in LumER+ cells but there was an inverse correlation between the Ptprb 
and Fgfr2 expression patterns in the MaSCs (Fig.6B,C). 
 
The in vitro organoid assay had already demonstrated that treatment with the FGFR ligand 
FGF2 promotes branching morphogenesis whilst suppressing Ptprb expression, supporting 
the inverse correlative relationship between Fgfr2 and Ptprb expression in vivo. We now 
tested whether two ligands for TEK, Angiopoietin1 and 2 (ANG1 and 2) could substitute for 
FGF2 in this assay. However, neither was able to stimulate branching (supplementary 
material Fig.S5B), suggesting the ANG-TEK axis is not involved in mammary branching 
morphogenesis. We therefore focussed on FGFR signalling and addressed whether PTPRB is 
a negative regulator of this pathway.  
 
As PTPRB is a cell surface receptor phosphatase, we hypothesised that it may be regulating 
phosphorylation of FGF receptors. We therefore tested in three independent experiments 
whether Ptprb knockdown altered baseline levels of FGFR phosphorylation as well as the 
response to FGF2. Indeed, transduction with the shPtprb 3820 virus significantly increased 
FGFR phosphorylation over shLuc control, both baseline levels and in response to FGF2. The 
effects of shPtprb 0145 were more modest, with a significant difference only seen after five 
minutes of FGF2 treatment (Fig. 7A and supplementary material Fig. S6). Note that pFGFR 
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antibodies cannot distinguish among the FGFR receptor isoforms, so it is not possible to 
determine which (or indeed if more than one) of the family shows increased phosphorylation 
in response to Ptprb knockdown. However, by using non-phospho-specific antibodies which 
do distinguish between the isoforms, we were able to demonstrate that total levels of FGFR1, 
2, 3 and 4 were not changed when Ptprb was knocked down (supplementary material Fig.S7 
and S8), confirming that the increase in pFGFR levels was indeed due to increased receptor 
phosphorylation not due to increased receptor expression. 
 
We next tested whether Ptprb knockdown altered the response of a downstream effector of 
FGF signalling, ERK1/2, to FGF2. First, we confirmed that branching in the organoid culture 
system in response to FGF2 was dependent on ERK1/2 activity, using a small molecule 
inhibitor of ERK (SCH772984; supplementary material Fig.S9 and Fig.S10). Next, organoids 
cultured in the in vitro branching assay system were transduced with either shLuc, shPtprb 
0145 or shPtprb 3820 knockdown virus and protein lysates collected either from unstimulated 
cultures or from cultures after 5, 15 and 60 minutes of FGF2 stimulation. In three 
independent experiments, Ptprb knockdown by both shPtprb 0145 and shPtprb 3820 resulted 
in a statistically significant increase in unstimulated baseline ERK1/2 phosphorylation 
compared with shLuc controls. In response to FGF2 stimulation, shPtprb 3820 cultures 
continued to show statistically significantly higher levels of phosphorylation at all time 
points, over and above the increased phosphorylation resulting from activation of the 
pathway. shPtprb 0145 cultures also showed higher mean phosphorylation but the differences 
in stimulated cultures were not statistically significant (Fig.7B and supplementary material 
Fig.S11). 
 
Finally, FGF-stimulated organoids in which Ptprb had been knocked-down by either shPtprb 
0145 or shPtprb 3820, were treated with SCH772984. In control cultures, knockdown 
organoids showed increased branching in response to FGF, as previously. However, 
treatment with the inhibitor partially restored branching back to control levels in shPtprb 
0145-transduced cultures and fully restored control branching levels in shPtprb 3820 cultures 
(Fig. 7C). Taken together, these findings support the model that PTPRB suppresses branching 
morphogenesis via inhibition of the FGFR2 – ERK1/2 signalling axis. 
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DISCUSSION 
Mammary epithelial development is a highly regulated process dependent on the interplay 
between systemically acting hormones and locally produced growth factors. During puberty 
rising levels of the ovarian steroid hormones oestrogen and progesterone, growth hormone 
secreted from the pituitary gland and locally produced growth factors cause a significant 
increase in ductal growth (Hennighausen and Robinson, 2001; Macias and Hinck, 2012). This 
growth is driven by bulbous TEBs, which form at the tips of elongating primary ducts and 
regularly bifurcate to form the primary branches of the ductal epithelium. As the mammary 
tree matures, secondary side branches sprout laterally at regular intervals, from which will 
form the tertiary lateral branches that occur at each diestrus and during pregnancy. The TEB-
tipped ducts grow until they reach the edge of the fat pad. At this stage, the TEBs regress and 
the subtending duct becomes relatively quiescent, leaving the branched ductal structures of 
the mature virgin gland (Hens and Wysolmerski, 2005). The unique “open architecture” of 
the non-pregnant gland suggests that branching morphogenesis is a highly regulated process, 
involving orchestrated ductal elongation, TEB bifurcation and lateral branching, which 
ensures space for additional proliferation and the formation of alveoli during pregnancy. A 
number of positive regulators of this process have been reported, such as the estrogen – 
estrogen receptor alpha (ER) axis and its downstream effectors, the growth hormone – growth 
hormone receptor – insulin-like growth factor 1 axis, epidermal growth factor receptor 
(EGFR) signalling and fibroblast growth factor receptor (FGFR) signalling. However, few 
negative regulators have been identified, Transforming growth factor beta 1 (TGFB1) and 
Sprouty 2 (SPRY2) being notable exceptions (Sternlicht, 2006; Sternlicht et al., 2006). Here, 
we have now identified PTPRB as a novel negative regulator of this process. 
 
In arterial endothelial cells, PTPRB activity enhances VE-cadherin-mediated adhesion 
(Nawroth et al., 2002) but is a negative regulator of TEK. Use of PTPRB inactivating 
antibodies in adult mice triggered activation of TEK, resulting in increased downstream 
signalling via ERK1/2 which in turn caused increased endothelial cell proliferation and 
enlargement of vascular structures (Winderlich et al., 2009). Thus, PTPRB is required to 
balance TEK activity and endothelial cell proliferation, thereby controlling blood vessel 
development and vessel size. This is supported by work in two independent germline Ptprb 
mouse knockout models, in which embryonic lethality occurred at around 10 days gestation 
due to severe vascular defects. In both models, vasculogenesis occurred normally but 
angiogenesis was severely affected leading to the deterioration of the intraembryonic vascular 
Soady et al.  PTPRB and mammary morphogenesis 
14 
 
system and lethality, demonstrating an essential role for PTPRB in angiogenesis and blood 
vessel remodelling (Baumer et al., 2006; Dominguez et al., 2007). 
 
In contrast to angiogenesis, in the mammary epithelium we find that PTPRB regulates 
morphogenesis by modulating FGFR signalling rather than TEK signalling. FGFRs can 
activate a number of potential downstream pathways, including PI3K/PIP2/AKT, 
PLC/IP3/Ca2+/Calmodulin and SOS/RAS/RAF/MEK/ERK. FGFR stimulates the 
SOS/RAS/RAF/MEK/ERK pathway by phosphorylation of Fibroblast Growth Factor 
Receptor Substrate 2 (FRS2), which in turn recruits GRB2, activating SOS and the 
downstream cascade (Katoh, 2009). Notably, SPRY2, another negative regulator of 
branching morphogenesis (Sternlicht, 2006; Sternlicht et al., 2006) is a negative regulator of 
FGF-induced ERK-pathway activation (Rubin et al., 2005), likely acting downstream of the 
GRB2-SOS complex (Gross et al., 2001). Here, we have demonstrated that knockdown of 
PTPRB results in higher baseline levels FGFR phosphorylation, resulting in higher levels of 
downstream p-ERK1/2 and a more sustained response to FGF2 stimulation, leading to a more 
densely  branched mammary tree. 
 
Evidence is emerging that PTPRB may be a tumour suppressor gene in a variety of cancers. 
Recurrent PTPRB loss-of-function mutations have been identified in angiosarcoma (in 10 of 
39 tumours examined) (Behjati et al., 2014), consistent with its normal role in angiogenesis, 
but also in metastatic melanoma (9 tumours with missense, nonsense or splice-site mutations 
out of a 97 tumour set) (Ding et al., 2014). Homozygous single nucleotide variations in 
PTPRB have also been reported in a rare family with siblings with glioblastoma multiforme; 
the parents were heterozygous for the mutations (Backes et al., 2014). No specific study of 
PTPRB in breast cancer has been undertaken, although Ptprb is a component of the MaSC 
gene signature we have identified as being prognostic in breast tumours (Soady et al., 2015). 
In contrast, a link between FGFR2 and breast cancer is well-established. FGFR2 gene 
amplification and FGFR2 protein overexpression (especially of C-terminally truncated 
products) occurs in primary ER+ breast cancer (Adnane et al., 1991; Katoh, 2003). The C-
terminally truncated product can activate signalling cascades in a ligand-independent manner 
(Moffa and Ethier, 2007). Missense point mutations also occur in primary breast cancer 
(Stephens et al., 2005) and SNPs in intron2 of FGFR2 are associated with an increased risk of 
ER+ breast cancer (Easton et al., 2007). Our findings suggest FGFR2 and PTPRB should be 
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considered as part of an integrated signalling pathway when assessing the activity of receptor 
tyrosine kinase signalling cascades in breast cancer. 
 
Our study does have limitations, including potential off-target and non-specific toxic effects 
of shRNA, as well as potential variable levels of viral infection and variable tropisms to 
different cell types. To offset the issue of infection levels, we chose a minimum cut-off of 
30% GFP-positive cells for analysis of organoids based on previously published work 
(Macias et al., 2011). Furthermore, the pattern of expression of FGF receptors in organoid 
cultures is unknown and any period of culture may alter the behaviour of epithelial cell 
subtypes compared with the in vivo situation. Nevertheless, the results of the study as a whole 
are consistent in supporting a role for PTPRB in regulating FGF-dependent branching 
morphogenesis. 
 
We cannot definitively distinguish between a role for PTPRB in TEB bifurcation, ductal 
elongation or lateral branching. However, the increased density of branching shown in Ptprb 
transplant outgrowths must have resulted from either a decrease in the rate of ductal 
elongation or an increase in the rate of formation of new branch points (either by TEB 
bifurcation or lateral branching). Ptprb knockdown resulting in a decrease in ductal 
elongation would not be consistent with our in vitro findings that Ptprb-knockdown 
organoids have more branches in response to FGF treatment. Furthermore, higher expression 
of Ptprb in subtending ducts relative to TEBs is at least correlative evidence that Ptprb may 
be suppressing lateral branching during ductal elongation, although the TEBs vs ducts study 
was carried out using C57/Bl6 mice, rather than FvB, and the possibility of strain-specific 
differences cannot be definitively excluded. Despite this caveat, when considered as a whole 
the data favour a model in which PTPRB is a negative regulator of FGFR-dependent 
branching, rather than ductal elongation. 
 
PTPRB has been typically characterised as a ‘vascular endothelial-specific’ phosphatase 
(Behjati et al., 2014). However, it is becoming clear that it has a wider role in other tissues. 
Its function in branching morphogenesis in both the vasculature and, as we have now shown, 
the mammary epithelium suggests that PTPRB is a fundamental regulator of this 
developmental program irrespective of organ system. Furthermore, its emerging role in 
cancer and the established importance of the pathway it regulates to tumour biology, reaffirm 
the relevance of developmental signalling programs to the biology of malignant disease. 
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MATERIALS AND METHODS 
Preparation of mammary epithelial cells for flow cytometry 
All animal work was carried out under UK Home Office project and personal licences 
following local ethical approval by the Institute of Cancer Research Animal Ethics 
Committee and in accordance with local and national guidelines. Single cells were prepared 
from fourth mammary fat pads of virgin female FVB mice as described (Regan et al., 2013) 
and stained with anti-CD24-FITC (clone M/69 at 1.0 µg/ml; BD Biosciences, Oxford, UK; 
catalogue #553261), anti-Sca-1-APC (clone D7 at 1.0 µg/ml; eBioscience, Hatfield, UK; 
catalogue #17-5981), anti-CD45-PE-Cy7 (clone 30-F11 at 1.0 µg/ml; BD Biosciences; 
catalogue #552848), anti-CD49f-PE-Cy5 (clone GoH3 at 5.0 µl/ml; BD Biosciences; 
catalogue #551129) and anti-c-Kit-PE (clone 2B8 at 1.0 µg/ml; BD Biosciences; catalogue 
#553355). Mammary epithelial cell subpopulations were defined as shown in supplementary 
material Fig.S1. For sorting of GFP+ cells harvested from transplanted fat pads, the 
combination of anti-CD24-Pacific Blue (clone M/69 at 1.0 µg/ml; BD Biosciences, Oxford, 
UK; catalogue #561079), anti-Sca-1-APC, anti-CD45-PE-Cy7 and DAPI was used. DAPI 
positive dead cells are distinguishable from Pacific Blue-stained cells by their very bright 
fluorescence. 
 
Gene expression analysis by quantitative real-time rtPCR (qPCR) 
Freshly sorted primary cells were lysed in RLT buffer (Qiagen, Crawley, West Sussex, UK) 
and stored at -80oC. Total RNA was extracted using an RNeasy MinElute Kit (Qiagen), 
according to the manufacturers' instructions. For cultured organoids RNA was isolated with 
Trizol (Invitrogen, Paisley, UK). qPCR reactions were performed as previously described 
using either TAQMAN assays or in-house designed probes (supplementary material Table 
S2) (Kendrick et al., 2008). All results were calculated using the Ct method compared to 
an endogenous control gene. Data were expressed as the mean fold gene expression 
difference in three independently isolated cell preparations over a comparator sample with 
95% confidence intervals. 
 
RNAScope in situ hybridisation for Ptprb 
RNAScope for Ptprb was performed on 5µm sections using RNAscope® 2.5 HD Duplex 
Reagent Kit using manufacturer’s instructions (Advanced Cell Diagnostics, Newark, CA, 
USA). RNAscope® Control Slides -Mouse 3T3 Cell Pellet were used to test the protocol. 
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Briefly, sections were cut and left to dry overnight at room temperature. Samples were then 
baked at 60°C for 1hour, then deparafinisation was performed (2x5min in Fresh Xylene) 
which was followed by 2x1min in 100% ethanol. Sections were then left to dry 5min at room 
temperature. Pretreat1 (H202) was then applied and left 10min at room temperature followed 
by 2 washed in distilled H20. Slides were then left to boil in Pretreat 2 (antigen retrieval) for 
15min and were then washed twice in distilled water (2x5min). Preatreat3 was applied 
(protease) on the slides for 30min at 40°C. After a couple of brief washes in distilled water, 
warmed probes were applied for 2hours at 40°C:  RNAscope® 2-plex Negative Control 
Probe (catalogue # 320751), Mm-Ptprb Cat No. 481391 in C2 channel (red), RNAscope® 2.5 
Duplex Positive Control Probe (Mm) PPIB-C1 (Green)/POLR2A-C2 (Red). After a couple of 
washes in the wash buffer, slides were left at room temperature overnight in 5XSSC. The 
next day, slides were incubated with several rounds of amplification Amp1-10 reagents 
following manufacturer’s instruction to detect red and green signal. Slides were finally 
counterstained 5 seconds in 50% filtered Mayer's Haemalum (Lamb/170D) and washed 
briefly in water then baked for 30min at 60°C. The slides were mounted using Vector Labs 
Vectamount (60mL) (catalogue # 321584). 
 
Lentivirus production 
Oligonucleotide pairs for shPtprb#1 (CACCGCGTCACCCTGTAACTTTAGCCGAA 
GCTAAAGTTACAGGGTGACGC and AAAAGCGTCACCCTGTAACTTTAGCTTCGGC 
TAAAGTTACAGGGTGACGC) and shPtprb#2 (CACCGCAAACACCTCCTTGGCTATCC 
GAAGATAGCCAAGGAGGTGTTTGC and AAAAGCAAACACCTCCTTGGCTATCTT 
CGGATAGCCAAGGAGGTGTTTGC) were ligated into pENTR/U6 Gateway system entry 
vector (Invitrogen, Paisley, UK) according to manufacturer’s instructions. Hairpin sequences 
were verified and then transferred, together with the U6 promoter, into a Gateway-modified 
pSEW lentiviral vector backbone (Vafaizadeh et al., 2010) by LR reaction (Invitrogen). Viral 
supernatants were generated by Lipofectamine 2000 (Invitrogen, #11668-019) co-transfection 
of the packaging and viral DNA sequence plasmids into HEK293T cells. Cells were re-fed 
with fresh medium (Dulbecco’s Modified Eagle’s Medium, DMEM; Invitrogen) plus 10% 
FCS (PAA Laboratories, GE Healthcare, Amersham, UK) after 24 hours. Supernatants were 
harvested 48 and 72 hours after transfection and assayed for absence of replication-competent 
virus. Supernatants were stored at -80oC until use. For transplantation assays, primary 
mammary cells were transduced with lentivirus using the suspension method as described 
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(Kendrick et al., 2008). Supernatants were adjusted by dilution where necessary to ensure 
comparable viral titres prior to transduction. 
 
Mammary epithelial cell transplantation 
Transplantation of lentivirus-transduced primary FVB mouse mammary epithelial cells into 
cleared fats pads of athymic Ncr Nude mice was carried out as described (Britt et al., 2009, 
Sleeman et al., 2007). Fat pads were harvested 8 weeks after transplantation, wholemounted 
and photographed under epifluorescent illumination. For size analysis, the area of the GFP+ 
outgrowths (defined by a continuous line around the outermost limit of the outgrowth) was 
determined using ImageJ with reference to a scale bar. For branching analysis, the number of 
branch points was counted in three 0.1cm2 fields per view per gland. The small size and 
difficulty in obtaining clear images of some outgrowths meant that not all of the outgrowths 
analysed for size were available for branching analysis. 
 
Mice were injected with control and knockdown cells in contralateral fat pads (shLuc vs 
shPtprb pool; shScr1 vs shPtprb 0145; shScr1 vs shPtprb 3820) to control for variability in 
growth between animals and variability in time at which glands were harvested, both of 
which will affect the size of the final outgrowth. 
 
For flow sorting analysis, GFP+ outgrowths were dissected out and processed to single cells, 
stained and analysed as described above. For secondary transplantation, GFP+ outgrowths 
were dissected out, processed to single cells and immediately re-transplanted. For histological 
analysis of transplants, small (5 mm3) pieces of GFP+ outgrowths were dissected out, 
formalin-fixed and paraffin embedded by standard methods. Dewaxed and re-hydrated 
sections underwent antigen retrieval in citrate buffer (0.01M, pH 6.0) for 18 min in a 
microwave (900W) before blocking in DAKO REAL Peroxidase blocking solution for 10 
minutes (Dako UK Ltd, Cambridgeshire, UK) for 30 min. Sections were incubated in Mouse 
on Mouse (M.O.M) Mouse Ig blocking reagent (Vector Laboratories, Peterborough, UK 
#BMK-2202) for 60 minutes followed by primary antibody for 60 minutes at room 
temperature, followed by M.O.M Biotinylated Anti-mouse IgG Reagent for 10 minutes. The 
secondary antibody was detected by application of Vectastain Elite ABC reagent for 5 
minutes followed by application of the chromogen 3,3'-Diaminobenzidine (DAB) for 5 
minutes (ABC, Vector Laboratories). Primary antibodies used were anti-K8/18 (clone 
Ks18.04, mouse monoclonal, catalogue #61028, Progen Biotechnik, Heidelberg, Germany; 
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diluted 1:2), anti-SMA (clone 1A4, mouse monoclonal, catalogue #A5691, Sigma, UK; 
diluted 1:500).  
 
For Immunofluorescence, sections were incubated in Mouse on Mouse (M.O.M) Mouse Ig 
blocking reagent for 60 minutes, followed by overnight incubation in primary antibody at 
4oC. Primary antibody was detected with an appropriate Alexafluor-conjugated secondary 
antibody. Images of stained sections were captured using a Leica TCS-SP2 microscope in 
three or four channels using Leica LCS software (Leica Microsystems, Milton Keynes, UK). 
Negative controls were performed using the same protocols with substitution of the primary 
antibody with IgG matched controls. In double staining experiments, control single stained 
sections in which either the primary antibody was left out or the primary antibody was 
combined with the wrong secondary antibody showed no staining. Primary antibodies used 
were, anti-SMA (clone 1A4, mouse monoclonal, catalogue #A5691, Sigma, UK; diluted 
1:500), anti-Ki67 (rabbit polyclonal, catalogue #ab16667, Abcam, UK; diluted 1:300), anti- 
cleaved caspase-3 (rabbit polyclonal, catalogue #9661S, Cell signalling, UK; diluted 1:100). 
Lung tissue from mice treated with four doses of doxorubicin at 2.5mg kg-1 and 
cyclophosphamide at 40mg kg-1 at five day intervals and then harvested five days after the 
final dose was used a positive control for cleaved caspase-3. 
 
Isolation and culture of mammary gland organoids 
Cultures were prepared as previously described (Fata et al., 2007; Ewald et al., 2008). 
Briefly, third and fourth mammary fat pad pairs were harvested virgin female 8-10 week old 
FVBn mice. Fat pads were minced and tissue shaken for 30-45 minutes at 37oC in 50 ml 1:1 
DMEM:Ham's F12 (Invitrogen), 5% FCS (PAA Laboratories) media with 3 mg/ml 
collagenase A (Roche Life Sciences, West Sussex, UK) and 3 mg/ml trypsin (Sigma). The 
collagenase solution was centrifuged at 1500 rpm for 10 min, dispersed through 10 ml 1:1 
DMEM:Ham’s F12, centrifuged at 1500 rpm for 10 min, and then resuspended in  5 ml 1 
μg/ml DNase I (Sigma) in serum free 1:1 DMEM:Ham's F12 medium. The DNase solution 
was shaken by hand at room temperature for 2-5 minutes then centrifuged at 1500 rpm for 10 
min. Organoids were separated from single cells through four differential centrifugations 
(pulse to 1500 rpm in 10 ml 1:1 DMEM:Ham’s F12). The final pellet was re-suspended in the 
desired amount of Growth Factor Reduced Matrigel (BD Biosciences) or 1:1 mix of Growth 
Factor Reduced Matrigel and lentivirus or 1:1 DMEM:Ham’s F12 for non-infected controls. 
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Organoid assays were carried out in 24-well plates. 50 μl of cold Growth Factor Reduced 
Matrigel was laid onto a sterile 13 mm diameter borosilicate glass coverslip and incubated for 
30 minutes at 37oC to solidify. 50μl of the organoid and Matrigel mix or organoid, Matrigel 
and lentivirus mix was plated over the solidified Matrigel and the plate incubated at 37oC for 
another 30 minutes. Once the Matrigel or 1:1 Matrigel:lentivirus mix containing the 
organoids had set, the organoids were covered with minimal media (1:1 DMEM:Ham's F12, 
5ug/ml insulin (Sigma) or branching medium (minimal medium + 50ng ml-1 FGF2 
(Peprotech, London, UK). ANG1 and ANG2 were a kind gift of Dr Andy Reynolds (Institute 
of Cancer Research, London, UK) and were also added at 50ng ml-1). For lentiviral 
transduction experiments, organoids with a minimum of ≥30% GFP positive cells were 
analysed, in line with previous studies (Macias et al., 2011). 
 
Protein analysis 
Transduced mammary organoids were serum starved for 12 hours and left unstimulated or 
stimulated with 10 ng/ml FGF2 for the indicated times. ERK1/2 inhibitor SCH772984 was 
obtained from Selleckchem (Newmarket, Suffolk, UK; #S7101). Organoids were released 
from Matrigel using non-enzymatic cell recovery solution (BD Biosciences) and then lysed in 
Laemmli buffer (2% SDS, 10% glycerol, 1.25% beta-mercaptoethanol, 0.002% bromphenol 
blue, 0.0625 M Tris pH 6.8). Following SDS-PAGE, protein extracts were transferred to a 
PVDF membrane and probed with antibodies to p44/42 MAPK (ERK1/2) (Cell Signalling 
Technologies, Leiden, The Netherlands, Antibody #9102), phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (Cell Signalling Technologies, Antibody #9101), phospho-FGF Receptor 
(Tyr653/654) (Cell Signalling Technologies, Antibody #3471), FGFR1 (9740, Cell Signaling, 
Technology, Rabbit monoclonal, clone D8E4), FGFR2 (H00002263-M01, Abnova,  Mouse 
monoclonal, clone 1G3), FGFR3 (PA5-34574, Rabbit polyclonal, ThermoFisher Scientific), 
FGFR4 (HPA028251, Rabbit polyclonal, Sigma Aldrich) or anti-tubulin (clone BM1A), 
Sigma, antibody #T6199). After incubation with peroxidase-conjugated secondary antibodies, 
immunocomplexes were detected using Enhanced Chemiluminescent (ECL) reagents. 
Densitometric analysis was performed using Image J software. 
 
Statistics 
Significance of gene expression differences analysed by qrtPCR were determined using 95% 
confidence intervals as described (Cumming et al., 2007). To test whether Ptprb knockdown 
decreased size of outgrowths but increased branching, one-tailed unpaired t-tests were used. 
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To determine whether Ptprb knockdown increased levels of ERK1/2 and FGFR 
phosphorylation in response to FGF2 stimulation, one-tailed unpaired t-tests were used. To 
determine differences in organoid branching, Chi2 test of distribution of categorical variables 
was used. 
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FIGURE LEGENDS 
Fig.1. Ptprb expression is repressed in mid-pubertal mammary epithelial cells. (A) 
Wholemounted fourth mammary fat pads from FVB mice at 3-4, 5-6 and 8-10 weeks old 
illustrating the extent of ductal developement. Bar = 3 mm. Magnified region of 3-4 week fat 
pad to show terminal end buds is enlarged 5x. (B) Relative Ptprb expression between MaSCs 
and MYO, MaSCs and LumER- and MaSCs and LumER+ populations (indicated by bars) 
determined by qPCR at three timepoints. The comparator sample is the LumER- population 
at each age group. **P<0.01, *P<0.05, N.S., not significant. (C) Relative Ptprb expression 
within each population across the three timepoints. Comparator was the 4-week-old sample 
for each population. Significance comparisons between 4-week and 6-week, 4-week and 8-
week and between 6-week and 8-week populations indicated by bars. **P<0.01, *P<0.05, 
N.S., not significant. Data in (B) and (C) were from three independent isolates of each cell 
population at each age. Data were normalised to β-actin and expressed as mean log10 relative 
fold expression (±95% confidence intervals) over the comparator.  
 
Fig.2. Ptprb knockdown promotes branching morphogenesis in vivo. (A) qPCR analysis 
of Ptprb gene expression in non-transduced primary mouse mammary epithelial cells and in 
cells transduced with either an empty virus, a control virus carrying a scrambled oligo 
sequence (shScr), a sequence targeting Luciferase (shLuc), or a virus pool consisting of two 
viruses (shPtprb 0145 and 3820) targeting Ptprb. (B) qPCR analysis of Ptprb gene expression 
in non-transduced cells and cells transduced with shScr virus or the individual shPtprb 0145 
and shPtprb 3820 viruses. Data in (A,B) presented as mean fold Ptprb expression (±95% 
confidence intervals; n=3 independent experiments) over comparator (non-transduced cells). 
*P<0.05 compared to non-transduced cells; **P<0.01 compared to non-transduced cells; 
##P<0.01 compared to shLuc or shScr transduced cells. (C) Representative images of GFP+ 
outgrowths in wholemounted fat pads eight weeks after transplant of control- or shPtprb-
transduced cells. Scale bar = 5 mm. Insets are magnified x3. Branch points in insets are 
indicated by arrowheads. For each shPtprb fat pad, the control shown next to it is a 
transplanted contralateral gland from the same animal. (D,E) Analysis of size (D) and 
branching (E) of control and shPtprb knockdown outgrowths (means±SEM). *P<0.05, 
**P<0.01, ***P<0.001. shLuc and shPtprb data from two independent transplant 
experiments; shScr, shPtprb 0145 and shPtprb 3820 data from three independent experiments. 
Numbers of fat pads analysed are provided in supplementary material Fig.S4A. 
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Fig.3. Ptprb knockdown increases mammary epithelial cell proliferation. (A, B) Staining 
of sections of shLuc (top rows) and shPtprb (bottom rows) outgrowths with anti-SMA and 
DAPI and either anti-K18 (A) or anti-Ki67 (B) antibodies. Scale bars = 100 μm. (C) 
Quantitation of Ki67 staining in luminal (SMA-) and basal (SMA+) layers of shPtprb 
outgrowths. Data shown as mean±SEM (n=8 regions from three independent control 
outgrowths and 11 regions from three independent Ptprb-knockdown outgrowths). (D) 
Analysis of areas (mm2) of outgrowths of shScr (n=8) and shPtprb 0145 (n=8) secondary 
transplants (mean±SEM). *P<0.05. 
 
Fig.4. Ptprb knockdown promotes branching morphogenesis in an in vitro model system. 
Non-infected (NI), shScr, shPtprb 0145 and shPtprb 3820 transduced organoids were 
embedded in Matrigel and stimulated to branch with FGF2 for five days in culture. Data from 
three independent experiments (duplicate wells for each treatment per experiment). GFP 
expression was used as a marker of lentivirus infection. A) Number of branched organoids as 
a percentage of the total number of organoids (mean±SD). *P<0.05 (t-test). B) Representative 
images of organoids with no branching (0 branches), low-level branching (1-5 branches), 
intermediate-level branching (6-15) and high-level branching (>15) Scale bar = 30μm. 
Merged GFP-fluorescence and phase contrast images. C) Extent of branching in non-infected 
(NI), shScr and Ptprb knockdown organoids. The proportion of organoids with low, 
intermediate or high level branching is shown as a percentage of the total number of branched 
organoids per treatment. *P<0.05; **P<0.01 (Chi2 test of distribution of categorical 
variables). 
 
Fig.5. FGF2 suppresses Ptprb expression in vitro. (A) Representative images of 
unmanipulated organoids in 3D culture either ‘non-stimulated’ (without growth factor; top 
panel) or ‘stimulated’ (with FGF2; bottom panel). Scale bars = 100 m. Arrowheads indicate 
branches emerging at day 4. Asterisks indicate organoids magnified 2.5 times in inset panels. 
B, C) Ptprb expression in non-stimulated and stimulated organoids, taken at 24 hour time 
points for 6 days, determined by qPCR. Data normalised to β-actin and expressed as mean 
log10 relative fold expression (±95% confidence intervals) over comparator population. Data 
collected from three independent organoid preparations. (B) Ptprb expression in stimulated 
organoids using the day 0 time point as the comparator sample. **P<0.01 compared to day 0; 
#P<0.01 compared to day 2 (t-tests). (C) Ptprb expression in non-stimulated and stimulated 
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organoids with expression levels in stimulated organoids compared to non-stimulated 
organoids at the same time point. **P<0.01 relative to comparator. 
 
Fig.6. Analysis of expression of candidate PTPRB-interacting receptor tyrosine kinases 
in mammary epithelial subpopulations. (A) Relative Ptprb, Fgfr2, Tek, Egfr, Fgfr1 and 
Igfr1 expression in MaSCs MYOs, LumER- and LumER+ populations determined by qPCR 
at mid-puberty (5 – 6 week samples). The comparator sample is the LumER- population in all 
cases. Ptprb data reproduced from Fig. 1 for reference. **P<0.01 vs LumER-, *P<0.05 vs 
LumER- ; ##P<0.01 vs MYO, #P<0.05 vs MYO; ^^P<0.01 vs LumER+, ^P<0.05 vs 
LumER+. For simplicity, significance is only shown compared to lower expressing samples. 
(B,C) Relative Ptprb, Fgfr2 and Tek expression in LumER+ cells (B) and MaSCs (C) at 3-4, 
5-6 and 8-10 weeks of age. The comparator was the 4-week-old sample for each population. 
Data were normalised to β-actin and expressed as mean log10 relative fold expression (±95% 
confidence intervals) over the comparator. Data from three independent isolates of each cell 
population at each age. Ptprb data reproduced from Fig. 1 for reference. **P<0.01 vs 3-4 
week samples, *P<0.05 vs 3-4 week samples. 
 
Fig.7. PTPRB suppresses FGFR2 signalling by negatively regulating ERK1/2. (A,B) 
Western blot analysis of phospho-FGFR levels (A) and phospho- and total-ERK1/2 levels (B) 
in shLuc-, shPtprb 0145- and shPtprb 3820-transduced primary mouse organoid cultures 
either unstimulated or stimulated with FGF2 for 5, 15 and 60 minutes. Blots are 
representative of three independent experiments; quantitation of phospho:total ERK1/2 ratios 
and phospho-FGFR:tubulin loading control ratios are shown below the blots (mean±SEM). 
*indicates a significant (P<0.05) increase over the shLuc control at that timepoint. The 
original blots are show in supplementary material Figs. S6 and S11. (C) Extent of branching 
in bFGF-stimulated shScr-organoids (Scr) and Ptprb knocked-down organoids (0145 and 
3820) stimulated with bFGF and treated or not with SCH772984 (2 nM). *P<0.05; 
***P<0.01 vs control FGF-stimulated samples (Chi2 test of distribution of categorical 
variables). 
